| Title |
Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals
|
|---|---|
| Published in |
International Journal of Chronic Obstructive Pulmonary Disease, October 2016
|
| DOI | 10.2147/copd.s115061 |
| Pubmed ID | |
| Authors |
Klaus Unfried, Ursula Krämer, Ulrich Sydlik, Andrea Autengruber, Andreas Bilstein, Sabine Stolz, Alessandra Marini, Tamara Schikowski, Stefanie Keymel, Jean Krutmann |
| Abstract |
Compatible solutes are natural substances that are known to stabilize cellular functions. Preliminary ex vivo and in vivo studies demonstrated that the compatible solute ectoine restores natural apoptosis rates of lung neutrophils and contributes to the resolution of lung inflammation. Due to the low toxicity and known compatibility of the substance, an inhalative application as an intervention strategy for humans suffering from diseases caused by neutrophilic inflammation, like COPD, had been suggested. As a first approach to test the feasibility and efficacy of such a treatment, we performed a population-based randomized trial. The objective of the study was to test whether the daily inhalation of the registered ectoine-containing medical device (Ectoin(®) inhalation solution) leads to a reduction of neutrophilic cells and interleukin-8 (IL-8) levels in the sputum of persons with mild symptoms of airway disease due to lifelong exposure to environmental air pollution. A double-blinded placebo-controlled trial was performed to study the efficacy and safety of an ectoine-containing therapeutic. Prior to and after both inhalation periods, lung function, inflammatory parameters in sputum, serum markers, and quality-of-life parameters were determined. While the other outcomes revealed no significant effects, sputum parameters were changed by the intervention. Nitrogen oxides (nitrate and nitrite) were significantly reduced after ectoine inhalation with a mean quotient of 0.65 (95% confidence interval 0.45-0.93). Extended analyses considering period effects revealed that the percentage of neutrophils in sputum was significantly lower after ectoine inhalation than in the placebo group (P=0.035) even after the washout phase. The current study is the first human trial in which the effects of inhaled ectoine on neutrophilic lung inflammation were investigated. Besides demonstrating beneficial effects on inflammatory sputum parameters, the study proves the feasibility of the therapeutic approach in an aged study group. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 81 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 16% |
| Student > Bachelor | 10 | 12% |
| Student > Ph. D. Student | 9 | 11% |
| Researcher | 6 | 7% |
| Student > Doctoral Student | 5 | 6% |
| Other | 13 | 16% |
| Unknown | 25 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 12% |
| Nursing and Health Professions | 9 | 11% |
| Biochemistry, Genetics and Molecular Biology | 7 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
| Agricultural and Biological Sciences | 4 | 5% |
| Other | 18 | 22% |
| Unknown | 27 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2020.
All research outputs
#1,094,777
of 25,374,917 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#46
of 2,577 outputs
Outputs of similar age
#20,174
of 332,577 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#2
of 96 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,577 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,577 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.